References
1. Grasselli G, Zangrillo A, Zanella A, et al. Baseline Characteristics and Outcomes of 1591 Patients Infected With SARS-CoV-2 Admitted to ICUs of the Lombardy Region, Italy. JAMA . 2020;323(16):1574-1581. doi:10.1001/jama.2020.5394
2. Saida IB, Ennouri E, Nachi R, et al. Very severe COVID-19 in the critically ill in Tunisia. Pan Afr Med J . 2020;35(136). doi:10.11604/pamj.supp.2020.35.2.24753
3. Yaghoubi A, Amel Jamehdar S, Movaqar A, Milani N, Soleimanpour S. An effective drug against COVID-19: reality or dream? Expert Rev Respir Med . 2021;15(4):505-518. doi:10.1080/17476348.2021.1854092
4. Yadav T, Srivastava N, Mishra G, et al. Recombinant vaccines for COVID-19. Hum Vaccines Immunother . 2020;16(12):2905-2912. doi:10.1080/21645515.2020.1820808
5. Lai CC, Chen IT, Chao CM, Lee PI, Ko WC, Hsueh PR. COVID-19 vaccines: concerns beyond protective efficacy and safety. Expert Rev Vaccines . 2021;20(8):1013-1025. doi:10.1080/14760584.2021.1949293
6. Al Khames Aga QA, Alkhaffaf WH, Hatem TH, et al. Safety of COVID-19 vaccines. J Med Virol . 2021;93(12):6588-6594. doi:10.1002/jmv.27214
7. Medeiros-Ribeiro AC, Aikawa NE, Saad CGS, et al. Immunogenicity and safety of the CoronaVac inactivated vaccine in patients with autoimmune rheumatic diseases: a phase 4 trial. Nat Med . 2021;27(10):1744-1751. doi:10.1038/s41591-021-01469-5
8. Beatty AL, Peyser ND, Butcher XE, et al. Analysis of COVID-19 Vaccine Type and Adverse Effects Following Vaccination. JAMA Netw Open . 2021;4(12):e2140364. doi:10.1001/jamanetworkopen.2021.40364
9. Cohen AF, van Gerven J, Burgos JG, et al. COVID-19 vaccines: the importance of transparency and fact-based education. Br J Clin Pharmacol . 2020;86(11):2107-2110. doi:10.1111/bcp.14581
10. Marcec R, Likic R. Postvaccination anaphylaxis and mRNA-based SARS-CoV-2 vaccines—Much ado about nothing? Br J Clin Pharmacol . 2021;87(9):3632-3633. doi:10.1111/bcp.14763
11. Karabulut K, Andronikashvili A, Kapici AH. Recurrence of Thrombotic Thrombocytopenic Purpura after mRNA-1273 COVID-19 Vaccine Administered Shortly after COVID-19. Konstantopoulos K, ed. Case Rep Hematol . 2021;2021:1-4. doi:10.1155/2021/4130138
12. Alislambouli M, Veras Victoria A, Matta J, Yin F. Acquired thrombotic thrombocytopenic purpura following Pfizer COVID‐19 vaccination. eJHaem . 2022;3(1):207-210. doi:10.1002/jha2.342
13. Yoshida K, Sakaki A, Matsuyama Y, et al. Acquired Thrombotic Thrombocytopenic Purpura Following BNT162b2 mRNA Coronavirus Disease Vaccination in a Japanese Patient. Intern Med Tokyo Jpn . 2022;61(3):407-412. doi:10.2169/internalmedicine.8568-21
14. Giuffrida G, Condorelli A, Di Giorgio MA, et al. Immune-mediated thrombotic thrombocytopenic purpura following Pfizer-BioNTech COVID-19 vaccine. Haematologica . 2021;107(4):1008-1010. doi:10.3324/haematol.2021.279535
15. Scully M, Hunt BJ, Benjamin S, et al. Guidelines on the diagnosis and management of thrombotic thrombocytopenic purpura and other thrombotic microangiopathies. Br J Haematol . 2012;158(3):323-335. doi:10.1111/j.1365-2141.2012.09167.x
16. Reese JA, Muthurajah DS, Kremer Hovinga JA, Vesely SK, Terrell DR, George JN. Children and adults with thrombotic thrombocytopenic purpura associated with severe, acquired Adamts13 deficiency: comparison of incidence, demographic and clinical features. Pediatr Blood Cancer . 2013;60(10):1676-1682. doi:10.1002/pbc.24612
17. Sessler CN, Gosnell MS, Grap MJ, et al. The Richmond Agitation-Sedation Scale: validity and reliability in adult intensive care unit patients. Am J Respir Crit Care Med . 2002;166(10):1338-1344. doi:10.1164/rccm.2107138
18. MOSCHCOWITZ E. Hyaline thrombosis of the terminal arterioles and capillaries : a hitherto undescribed disease. ProcNY Pathol Soc . 1924;24:21-24.
19. Knöbl P. Thrombotic thrombocytopenic purpura. Memo . 2018;11(3):220-226. doi:10.1007/s12254-018-0429-6
20. Chamarti K, Dar K, Reddy A, Gundlapalli A, Mourning D, Bajaj K. Thrombotic Thrombocytopenic Purpura Presentation in an Elderly Gentleman Following COVID Vaccine Circumstances. Cureus . 2021;13(7):e16619. doi:10.7759/cureus.16619
21. Al‐Ahmad M, Al‐Rasheed M, Shalaby NAB. Acquired thrombotic thrombocytopenic purpura with possible association with AstraZeneca‐Oxford COVID‐19 vaccine. eJHaem . 2021;2(3):534-536. doi:10.1002/jha2.219
22. Waqar SHB, Khan AA, Memon S. Thrombotic thrombocytopenic purpura: a new menace after COVID bnt162b2 vaccine. Int J Hematol . 2021;114(5):626-629. doi:10.1007/s12185-021-03190-y
23. Bendapudi PK, Hurwitz S, Fry A, et al. Derivation and external validation of the PLASMIC score for rapid assessment of adults with thrombotic microangiopathies: a cohort study. Lancet Haematol . 2017;4(4):e157-e164. doi:10.1016/S2352-3026(17)30026-1
24. Li A, Khalighi PR, Wu Q, Garcia DA. External validation of the PLASMIC score: A clinical prediction tool for thrombotic thrombocytopenic purpura diagnosis and treatment. J Thromb Haemost JTH . 2018;16(1):164-169. doi:10.1111/jth.13882
25. Giuffrida G, Condorelli A, Di Giorgio MA, et al. Immune-mediated thrombotic thrombocytopenic purpura following Pfizer-BioNTech COVID-19 vaccine. Haematologica . Published online 12 August 2021. doi:10.3324/haematol.2021.279535
26. de Bruijn S, Maes M, De Waele L, Vanhoorelbeke K, Gadisseur A. First report of a de novo iTTP episode associated with an mRNA‐based anti‐COVID‐19 vaccination. J Thromb Haemost . 2021;19(8):2014-2018. doi:10.1111/jth.15418
27. Innao V, Urso S, Insalaco M, Borraccino A, Consoli U. Immune Thrombotic Thrombocytopenic Purpura following Pfizer-BioNTech anti-COVID-19 vaccination in a patient healed from lymphoma after allogeneic hematopoietic stem cell transplantation. Thromb Res . 2022;210:91-93. doi:10.1016/j.thromres.2021.12.029
28. Lee HP, Selvaratnam V, Rajasuriar JS. Thrombotic thrombocytopenic purpura after ChAdOx1 nCoV-19 vaccine. BMJ Case Rep . 2021;14(10):e246049. doi:10.1136/bcr-2021-246049
29. Maayan H, Kirgner I, Gutwein O, et al. Acquired thrombotic thrombocytopenic purpura: A rare disease associated with BNT162b2 vaccine. J Thromb Haemost JTH . 2021;19(9):2314-2317. doi:10.1111/jth.15420
30. Pavenski K. Relapse of Immune Thrombotic Thrombocytopenic Purpura Following Vaccination with COVID19 mRNA Vaccine. TH Open . 2021;05(03):e335-e337. doi:10.1055/s-0041-1732342
31. Klok FA, Pai M, Huisman MV, Makris M. Vaccine-induced immune thrombotic thrombocytopenia. Lancet Haematol . 2022;9(1):e73-e80. doi:10.1016/S2352-3026(21)00306-9
32. Aleem A, Nadeem AJ. Coronavirus (COVID-19) Vaccine-Induced Immune Thrombotic Thrombocytopenia (VITT). In: StatPearls . StatPearls Publishing; 2022.
33. Osmanodja B, Schreiber A, Schrezenmeier E, Seelow E. First diagnosis of thrombotic thrombocytopenic purpura after SARS-CoV-2 vaccine – case report. BMC Nephrol . 2021;22(1):411. doi:10.1186/s12882-021-02616-3
34. Sissa C, Al-Khaffaf A, Frattini F, et al. Relapse of thrombotic thrombocytopenic purpura after COVID-19 vaccine. Transfus Apher Sci . 2021;60(4):103145. doi:10.1016/j.transci.2021.103145
35. Yocum A, Simon EL. Thrombotic Thrombocytopenic Purpura after Ad26.COV2-S Vaccination. Am J Emerg Med . 2021;49:441.e3-441.e4. doi:10.1016/j.ajem.2021.05.001
36. Deucher W, Sukumar S, Cataland SR. Clinical relapse of immune-mediated thrombotic thrombocytopenic purpura following COVID-19 vaccination. Res Pract Thromb Haemost . 2022;6(1):e12658. doi:10.1002/rth2.12658
37. Kirpalani A, Garabon J, Amos K, et al. Thrombotic thrombocytopenic purpura temporally associated with BNT162b2 vaccination in an adolescent successfully treated with caplacizumab. Br J Haematol . 2022;196(1):e11-e14. doi:10.1111/bjh.17782
38. Ruhe J, Schnetzke U, Kentouche K, et al. Acquired thrombotic thrombocytopenic purpura after first vaccination dose of BNT162b2 mRNA COVID-19 vaccine. Ann Hematol . 2022;101(3):717-719. doi:10.1007/s00277-021-04584-y
39. Picod A, Rebibou JM, Dossier A, et al. Immune-mediated thrombotic thrombocytopenic purpura following COVID-19 vaccination. Blood . Published online 10 March 2022:blood.2021015149. doi:10.1182/blood.2021015149
40. Zheng XL, Vesely SK, Cataland SR, et al. ISTH guidelines for treatment of thrombotic thrombocytopenic purpura. J Thromb Haemost JTH . 2020;18(10):2496-2502. doi:10.1111/jth.15010
41. Hanlon A, Metjian A. Caplacizumab in adult patients with acquired thrombotic thrombocytopenic purpura. Ther Adv Hematol . 2020;11:1-10. doi:10.1177/2040620720902904